ASCRS 2023: The introduction of SeeLuma and more

Video

Anthony Wallace, Vice President and General Manager of the US Surgical Business at Bausch + Lomb, discussed the introduction of SeeLuma, a fully digital surgical visualization platform, and more at the 2023 ASCRS annual meeting in San Diego.

Anthony Wallace, Vice President and General Manager of the US Surgical Business at Bausch + Lomb, discussed the introduction of SeeLuma, a fully digital surgical visualization platform, and more at the 2023 ASCRS annual meeting in San Diego.

Video transcript

Editor’s note: Transcript lightly edited for clarity.

Anthony Wallace:

Hi everyone. My name is Anthony Wallace and I'm the Vice President and General Manager of the US Surgical Business at Bausch + Lomb. We're really excited to be here with you this week at ASCRS to share some of our latest updates that we're coming to the market with. The first is the introduction of SeeLuma. SeeLuma is our fully digital surgical visualization platform. SeeLuma offers optical surgeons a new level of visualization, compared to optical, hybrid and retrofitted microscopes. Some of the key features of SeeLuma include a heads-up 3D monitor, multiple digital display options, and an intuitive interface that really leads to outstanding surgical visualization, ergonomics, workflow, and a truly immersive educational experience. Built for the most complex surgical cases, SeeLuma is available in the United States as well as in Western Europe, and we soon plan to bring SeeLuma to additional markets in the near future.

In addition to SeeLuma, we recently announced the launch of StableVisc cohesive OVD as well as TotalVisc OVD System. TotalVisc is the only available dual-pack, cohesive and dispersive OVD in the United States that is formulated with sorbitol. Sorbitol is a chemical agent known to have excellent physical barrier capability as well as increased free radical scavenging capabilities. With the recent acquisition of AcuFocus, our portfolio now includes the Apthera IC-8 IOL. The Apthera IC-8 is the first, and only small aperture, nontoric extended depth-of-focus IOL for select cataract patients with as much as 1.5 diopters of corneal astigmatism, who wished to correct presbyopia at the same time. We're really excited about some of these updates and sharing additional information with you and we look forward to continuing our partnership and helping patients see better to live better. Thank you.

Related Videos
Charissa Lee, OD, MBA, FAAO, talks DEI in leadership roles in optometry
GWCO past-president and treasurer outline the 2024 Congress event in October
Derek Bryant, 2024 AOSA president
Kurt Moody, OD, FAAO, describes how to fit multifocal contact lenses in a way that patients love
Tracy Lynn Schroeder Swartz O.D., M.S., FAAO, overviews her talk on comanagement
Susan Gromacki, OD, MS, FAAO, FSLS
Nick Bruns, OD, FAAO, talks premium IOLs and EVO ICL at AOA 2024.
Mohammad Rafieetary, OD, FAAO
Susan Gromacki, OD, MS, FAAO, FSLS
Megan Cavet, PhD
© 2024 MJH Life Sciences

All rights reserved.